Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

ence of transmission of HBV, HCV, or HIV, and no clinically relevant anti-C1 inhibitor antibodies developed

In a poster entitled, 'Open-Label Use of Nanofiltered C1 Esterase Inhibitor (human) (nf-C1 INH) for the Prophylaxis of Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects,' Dr. Colin Broom M.D., ViroPharma Incorporated, Exton, PA, presented new open label results of Cinryze in preventing HAE attacks in 23 pediatric patients with HAE.  Data from this study included the following:

  • Cinryze reduced the frequency of HAE attacks from a median of 3.0 attacks per month at baseline to 0.39 attacks per month during Cinryze prophylaxis
  • In children, prophylactic doses of 1000 U of Cinryze every 3 to 7 days resulted in increases in antigenic and functional C1-INH levels comparable to those seen in adults; increases in functional C1-INH activity were maintained over time
  • There were no severe hypersensitivity reactions related to Cinryze; no discontinuations from study due to adverse events; no detectable anti-C1 INH antibodies; and no evidence of transmission of HBV, HCV, or HIV;
  • Adverse events considered to be possibly, probably, or definitely related to Cinryze were headache, nausea, and infusion site erythema, none of which were considered severe.

In addition, the WAO has joined with The American College of Allergy, Asthma and Immunology (ACAAI) and the American Gastroenterological Association (AGA) Institute in an innovative  initiative called "HAE:  Learn About It, Talk About It."  The peer-driven campaign is designed to foster communication between physicians on the front lines of the diagnosis and management of HAE. The addition of WAO as a "Learn About It, Talk About It" partner expands the program to a global audience. The program will be highlighted in booth 13 at the WAO meeting.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 /PRNewswire-iReach/ -- MHG Medical Management ... launched its Medical Equipment and X-ray Annual ... are tailored to the cruise industry,s unique requirements.  ... operators to propose that they should develop a ... program is intended to create standardized processes and ...
(Date:7/29/2014)... YORK , July 29, 2014 McGraw-Hill ... services for the science, technical, and medical communities, has ... the first off-line mobile application of the world-renowned medical ... the new AccessMedicine App , available for download ... will now be able to gain access to valuable ...
(Date:7/29/2014)... (SIX: RO, ROG; OTCQX: RHHBY) launched its presence at ... Lab Expo today by unveiling two booths (#1209 and ... with customers to redefine the value of the laboratory. ... they,re looking for a partner to help them maximize ... said Jack Phillips , president and CEO of ...
Breaking Medicine Technology:MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... - Amgen,(Nasdaq:AMGN) today presented the results from a ... safety of Aranesp(R) (darbepoetin alfa) for the,treatment of ... or radiotherapy ("the 103 study"). Aranesp is not,approved ... these patients. These,results were presented in an oral ...
... therapeutic approach for the treatment,of early and metastatic ... - AEterna,Zentaris Inc. , a global, pure play ... presented an,abstract outlining in vivo data for its ... at the American,Association for Cancer Research (AACR) Annual ...
Cached Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 2AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist,JMR-132 at the AACR Annual Meeting in Los Angeles 3
(Date:7/29/2014)... IRVINE, CA (PRWEB) July 29, 2014 July ... and at home care, is proud to announce that it ... for two inspiring online video segments; Silverado Through a ... Endeavor . , In Silverado Through a Child's ... work with her mom at Silverado Beverly Place, a memory ...
(Date:7/29/2014)... The Transformer Oil Market in Europe report defines and segments ... of revenue. The Transformer Oil market in Europe is estimated ... billion by 2018, at a CAGR of 7.8% from 2013 ... Oil Market in Europe report, to get an idea of ... the segmentation in the Transformer Oil market in Europe, and ...
(Date:7/29/2014)... According to a new report series by iData ... medical device market research, the Global Cardiac Surgery ... billion by 2018. This growth will be fueled by ... market, which is comprised of both the transcatheter heart ... (TMVR) segments. , There are many risks associated with ...
(Date:7/29/2014)... 29, 2014 This month, Therapy ... Blocks to a Successful, Balanced Career.” The guide is ... path, seeking guidance on creating a successful career. ... from focus, determination, and understanding your strengths and limits,” ... “This guide will uncover the elements to creating balance ...
(Date:7/29/2014)... July 29, 2014 According to the ... both the recreational and the medicinal sectors is mirroring ... marijuana becomes more accepted in mainstream culture, many are ... from the traditional and more dangerous forms of smoking ... becoming quite the trend in legalized states such as ...
Breaking Medicine News(10 mins):Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Transformer Oil Market is Expected to Reach $0.5 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Therapy Changes Releases New Guide to Building a Successful Career 2Health News:Marijuana Edibles Sales Show Growth in Market 2
... the development of muscles.Da-Zhi Wang and other researchers of the ... the genes are among a recently discovered group of genes ... in the past few years have they been recognised as ... study authors said in an article that appeared in the ...
... experience with China, Pakistani pharmaceutical companies are keen to ... government // to relax the stringent visa norms. ... raw materials provided by the Chinese, apart from the ... problems with the Chinese, though their rates are cheaper ...
... Research Center has reported that maintaining the current recommended ... of cardiovascular disease. The researcher has asked the ... patients less than the recommended levels by aggressive blood ... is used to monitor the average amount of blood ...
... Baruch College has reported in his recent article that having ... . Dr. Brind has compiled data from recent studies of ... American Physicians and Surgeons. ,Professor Brind, ... that pregnancies leading to miscarriage or induced abortions does not ...
... obese people are in increased risk of developing eye ... Belkin and Zohar Habot-Wilner // , Goldschleger Eye Institute, ... and found that risk of developing eye problems are ... link between obesity and other chronic diseases and cancers. ...
... cholesterol can do to people. High-fat diets cause many patients' ... // to know what they consume. ,Now, new rules ... avoid trans fats, which plug arteries, and have been linked ... ,Trans fats are a result of manufacturers adding ...
Cached Medicine News:Health News:Pakistan drug companies seek trade ties with India 2Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3
Spectrafuge 16M High speed microcentrifuge. High g-force for molecular biology applications. Brushless, maintenance-free motor. Easy to use control panel. Complete with 18 x 1.5/2.0 ml rotor. StripSp...
... two centrifuges -- the world's most popular ... in one reliable, quiet, compact unit. It ... two separate centrifuges!, For your microcentrifuge needs, ... supplies you with the MicroMB centrifuge, microcentrifuge ...
... Centrifuge 4-15C is designed to accommodate the deep-well ... necessary force of more than 5600 x g ... of both fixed-angle and swing-out rotors are available ... 15 ml, and 50 ml tubes, as well ...
... Model 5415D is an ideal workhorse for the ... of time and speed/g-force. , Product features ... , Compact 9 x 12-inch (W x D) ... a cold room , 24-place capacity ...
Medicine Products: